Abstract A208
. Variant detection in circulating plasma DNA and concordance
Variant detection in Circulating Plasma DNA
A total of six plasma DNA samples, collected from four NSCLC patients were sequenced with the (NSCLC) accounts for 85% of lung cancers. Several contributing oncogenes including anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and/or Kirsten rat sarcoma (KRAS) have been targeted by kinase inhibitors either approved or in development to treat NSCLC patients. Studies have shown that the types and locations of the mutations in ALK, EGFR or KRAS can serve as biomarkers to predict clinical response to these targeted therapies. Determination of mutation status for these oncogenes thus provides guidance for the choice of a potential therapy.
The poor quality of the DNA obtained from formalin fixed paraffin-embedded (FFPE) tumor tissue, and the limited quantity of the DNA obtained from the circulating plasma DNA present technical obstacles to frequent and effective mutation profiling for the cancer patients
In the four sequencing runs performed with 316 chip in this study, the library coverage ranges from~5000x read depth to~15000x read depth ( Table 5 ). The coverage across the ALK-EGFR-KRAS NGS Panel ROI was uniform, and above 98.8% amplicons had more than 1000x coverage, in the libraries prepared from the cell line DNA, the FFPE DNA, and the circulating plasma Table 9) . Each of these variants was confirmed by the obtained from the circulating plasma DNA, present technical obstacles to frequent and effective mutation profiling for the cancer patients. Next Generation DNA Sequencing (NGS) offers parallel sequencing of tens to hundreds of exons with sensitivities to at least 5%. The short read sequencing chemistry of NGS is ideal for FFPE DNA which is typically fragmented. In addition, the library preparation chemistry of the Ion AmpliSeq NGS platform, which requires only minimal DNA input, makes it possible for the circulating plasma DNA to be used in comprehensive mutation detection. Here we report the results from a proof-of-concept study using a custom Ion AmpliSeq NGS panel designed to sequence a range of clinically relevant exons in ALK, EGFR and KRAS genes in both FFPE DNA and plasma circulating DNA.
DNA tested, and with both Primer Pools ( 
Materials and Methods
The cumulative 1.8 kb regions of interest (ROI) include exons 20-25 of ALK, exons 18-22 of EGFR, and exons 2-4 of KRAS, as well as the intronic 3 bp at intron-exon boundaries ( Table 1 and Figure 1 ). Two pools of the primers to sequence the ROI were designed using Ion AmpliSeq Designer. Two libraries were prepared for each DNA sample with Ion AmpliSeq Library Kit 2.0, using two separate pools of primers.
The DNA input per library is 10 ng for cell line or FFPE DNA, or 0.5-2 ng for circulating plasma DNA. Each library was uniquely barcoded. The libraries were amplified on the OneTouch system using OneTouch OT2 In addition, another Genomic DNA Reference Standard from Horizon Diagnostics, the ALK F1174L with 50% allele frequency, was serially diluted into NA12878 to generate samples with expected frequencies of 10%, 3% and 1%. The DNA samples of these dilutions were sequenced with ALK-EGFR-KRAS NGS Panel, and the results indicated that the ALK variant was observed Horizon Diagnostics reference DNA samples, the FFPE DNA samples, and the circulating plasma DNA samples, were concordant with those from the other methods, including the Horizon Diagnostics ddPCR (for the Horizon Diagnostics reference DNA samples), the Ion Torrent and Illumina commercial cancer panels (for the FFPE DNA samples), and the Qiagen RGQ assay and MolecularMD proprietary EGFR ddPCR assay (for the circulating plasma DNA) (Figure 3) . Only one additional mutation (the EGFR exon 19 deletion) identified by RGQ was not detected by the ddPCR assay or the NGS Panel ( Table 9) . No potential false positives were identified in this study. (Table 7) . Additionally, a variant in KRAS, which was in the HCT-116 cell line harboring the engineered ALK F1174L mutation, was also detected at the expected frequency ( Table 7) .
Conclusions
• This study demonstrates the feasibility of creating a sensitive and specific ALK-EGFR-KRAS focused NGS assay that covers broader regions of the target genes than the hotspots represented in the commercial panels.
• With a minimum total DNA input of 20 ng of FFPE DNA, or 1 ng of the plasma circulating DNA, the assay was able to detect both SBS and small indels in the targeted regions, with the LOD of~1%. Variant Detection in FFPE DNA Samples Eight FFPE DNA samples were blinded and sequenced with the ALK-EGFR-KRAS NGS Panel (10 ng input per primer pool). Five unique KRAS mutations were detected in these samples, which were confirmed by the results from the commercial cancer panels (Table 8 ). In addition, the frequencies observed for these mutations were comparable to the frequencies observed for these mutations by either of the cancer panels No additional mutations were
• Given the low DNA input requirements and the capability of plasma-based testing, this assay and other custom NGS panels may enable routine monitoring of mutation status for relevant genes in patients with various solid tumors, and may ultimately inform clinical decision-making. mutations by either of the cancer panels. No additional mutations were identified in these samples by the ALK-EGFR-KRAS NGS Panel, which is consistent with the results from the commercial cancer panels, although the commercial panels only partially cover the ROI covered by the ALK-EGFR-KRAS NGS Panel.
